hotspot -WSS

hotspot

author：knowledge 2025-09-06 02:05:53 - browse：1

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： STAT series 'Denied by AI' wins major journalism prizes

entertainment

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Walmart eyes Medicare Advantage provider ChenMed

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Hottest summer in 2,000 years puts focus on extreme heat, health

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Supreme Court to hear if Covid misinformation is protected speech

leisure time

hotspot

focus

Jerome Adams on the need for new antivirals for Covid

Hospitals consider fixing cancer drug shortages on their own

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Oak Street deal isn't the answer to health care's woes

Hepatitis C has a cure — but many Americans still lack access to it

Walmart eyes Medicare Advantage provider ChenMed

United colonoscopy coverage change 'may cost lives,' doctors say

ALS treatment from Biogen, Ionis fails in study

Duchenne breakthrough therapy leaves behind pioneering families

Cherokee Nation medical school graduates its first class

hotspot

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

FDA proposes changes to key medical devices approval pathway

Generate Biomedicines machine learning biotech raises $273M

Generate Biomedicines machine learning biotech raises $273M

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

entertainment

focus

leisure time

focus